ArticleImmunology2002
Reactivation of latent tuberculosis by an inhibitor of inducible nitric oxide synthase in an aerosol murine model.
Article in Immunology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Cell-mediated immune responses of beta-glucan on the pathogenesis of chronic tuberculosis infection.Frontiers in immunology · 2026Review
- Therapeutic Modulation of Arginase with nor-NOHA Alters Immune Responses in Experimental Mouse Models of Pulmonary Tuberculosis including in the Setting of Human Immunodeficiency Virus (HIV) Co-Infection.Tropical medicine and infectious disease · 2024Article
- Helper T cell bias following tuberculosis chemotherapy identifies opportunities for therapeutic vaccination to prevent relapse.NPJ vaccines · 2023Article
- Immunological aspects of host-pathogen crosstalk in the co-pathogenesis of diabetes and latent tuberculosis.Frontiers in cellular and infection microbiology · 2022Article
- Article
- Small Animal Model of Post-chemotherapy Tuberculosis Relapse in the Setting of HIV Co-infection.Frontiers in cellular and infection microbiology · 2020Article
- Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis.Frontiers in cellular and infection microbiology · 2018Review
- Animal Models for Tuberculosis in Translational and Precision Medicine.Frontiers in microbiology · 2017Review
- The emerging role of gasotransmitters in the pathogenesis of tuberculosis.Nitric oxide : biology and chemistry · 2016Review
- Naturally produced opsonizing antibodies restrict the survival of Mycobacterium tuberculosis in human macrophages by augmenting phagosome maturation.Open biology · 2015Article
- Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2011Article
- Redundant and pathogenic roles for IL-22 in mycobacterial, protozoan, and helminth infections.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Airway delivery of silica increases susceptibility to mycobacterial infection in mice: potential role of repopulating macrophages.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- The role of resuscitation promoting factors in pathogenesis and reactivation of Mycobacterium tuberculosis during intra-peritoneal infection in mice.BMC infectious diseases · 2007Article
- Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis.Clinical and experimental immunology · 2007Review
- Deletion of the Mycobacterium tuberculosis resuscitation-promoting factor Rv1009 gene results in delayed reactivation from chronic tuberculosis.Infection and immunity · 2006Article
- Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis.Gene therapy · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Exposure to Mycobacterium tuberculosis results in clinical tuberculosis only in a small percentage of healthy individuals. In most instances the bacilli are controlled by the immune system and survive in a latent state within granuloma. Immunosuppression, however, may result in reactivation of infection, resulting in clinical disease. Using a low-dose aerosol infection (30 colony-forming units) in mice, we describe a short-duration model for studying spontaneous and drug-induced reactivation of anti-tuberculous drug-treated, latent tuberculosis infection. Although a 4-week treatment with rifampicin and isoniazid reduced the number of bacilli to undetectable levels, the infection spontaneously reactivated following therapy. By contrast, an 8-week treatment period induced a state of latent infection, requiring immunosuppression to reactivate infection. Finally, a 12-week treatment period eliminated the bacilli completely and aminoguanidine did not induce reactivation of infection. In view of the fact that therapy in the selected protocol reduces the mycobacterial load to undetectable levels, the data suggest that an 8-week treatment period is necessary and sufficient to mount protective immunity in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.